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Objectives: To estimate the efficacy and safety of glycopirronium-indacaterol 
(GLN/IND) as maintenance therapy for moderate to severe chronic obstructive pul-
monary disease (COPD) compared to other first-line treatments, through a system-
atic review and meta-analysis. MethOds: A detailed search was performed in eight 
electronic databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, 
Cochrane Database of Abstracts of Reviews of Effects (DARE), LILACS, Cochrane 
Central Register of Randomized Controlled Trials, WHO International Clinical Trials 
Registry Platform, ClinicalTrials.gov) searching for clinical trials that compared effi-
cacy and/or safety of glycopirronium (GLN) alone or GLN/IND as first-line drugs 
for moderate to severe COPD. Seven functional and quality of life outcomes were 
collected. An expert panel supported and validated the methodology. Finally, a 
meta-analysis was performed when the homogeneity of the information permit-
ted. Results: 14.349 references were originally identified, 13.253 were left after 
eliminating duplicates, and were reviewed by two researchers; 112 full-text articles 
were retrieved, and finally 13 provided useful information and were included in the 
analysis. Studies comparing tiotropium (TIO) with GLN didn’t show statistically 
significant differences in efficacy or safety. Studies comparing GLN/IND against TIO, 
showed statistically significant results, favoring GLN/IND, for “trough FEV1 “ (a func-
tional indicator), as well as for, both quality of life scales (Transition Dyspnea Index 
TDI and Saint Georges Respiratory Questionnaire SGRQ). With respect to safety, GLN/
IND and all first drugs have a similar profile. cOnclusiOns: We conclude that GLN/
IND is more effective than other first-line drugs in the management of moderate to 
severe COPD, with a similar safety profile.
PRS5
DoctoRS’ FailuRe in obSeRvance oF the coPD ManageMent guiDelineS: 
the czech RePublic 2015 uPDate
Zigmond J1, Vitova V1, Koblizek V2, Zatloukal J3, Kolek V3
1CEEOR s.r.o., Prague, Czech Republic, 2Charles University, Faculty of Medicine and University 
Hospital, Hradec Kralove, Czech Republic, 3Olomouc University Hospital, Olomouc, Czech Republic
Objectives: The primary objective of this study was to update the results of the 
examination of GOLD 2011 COPD management recommendation implementation 
among the Czech respiratory specialists with respect to the patients’ classification. 
The secondary objective was to explore effect of a misclassification on the use of 
inhaled corticosteroids (ICS). MethOds: Multicenter cross-sectional study was con-
ducted among COPD specialists, consisting of general questionnaire and patient-
specific forms. A subjective classification into the GOLD 2011 groups as practiced by 
the healthcare professionals was examined and then compared with the objective 
classification achieved by rigorous software-computed classification. Results: There 
were significant differences between patient’s objective and subjective GOLD clas-
sification. The ratio in percent of the patients was as follows: A 26.4/14.9, B 20.0/28.4, 
C 12.7/24.3 and D 40.9/30.8. The best match was found between D category, followed 
by B, A and C. About 45% of the doctors assign patients to the GOLD category incor-
rectly disregarding whether they were using GOLD classification or not. One sixth of 
the patients received inhalation corticosteroids, half of those incorrectly. About four 
percent of the patients received iPDE4, half of those incorrectly. More than two thirds 
of the patients (75.9%) received LABA in any combination or alone. About half of the 
patients (57.4% and 46.3%) received LAMA or ICS in any combination or alone. Three 
most common objectively assign phenotypes were emphyzematic, bronchitic and 
repeated exacerbations phenotypes. The same results were obtained for subjectively 
assign phenotypes. The most common objective overlap phenotypes were bronchitic 
& emphyzematic, bronchitic & repeated exacerbations and bronchitic & emphyzem-
atic & repeated exacerbations overlap phenotypes. The same results were obtained 
for subjective phenotypes. cOnclusiOns: Despite high awareness of the GOLD 2011 
guidelines, its implementation is insufficient. Doctors therefore both assign patients 
to the wrong GOLD category and prescribe inadequate drugs, specifically ICS.
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Objectives: To assess the comparative efficacy and safety of monoclonal antibodies 
and a tyrosine-kinase inhibitor for severe or uncontrolled asthma, using a Bayesian 
network meta-analysis. MethOds: A systematic literature review was conducted 
according to NICE guidelines. Outcomes of interest included asthma control ques-
tionnaire (ACQ) score, asthma exacerbations and discontinuations due to adverse 
events (AE). Identified studies assessed mepolizumab, lebrikizumab, omalizumab and 
masitinib. Networks of evidence were based on treatment- and dose-specific nodes 
except for masitinib (results were only reported for pooled doses). Interpretation of 
results was based on absolute differences/ratios and Bayesian probabilities for treat-
ments to perform better than others (P), where P≤ 15% indicated a smaller effect and 
P≥ 85% a larger effect. Vague prior distributions were used. Results: 8/6/3 studies 
reported results at 16/26/52 weeks respectively. Analyses indicated that active treat-
ments and placebo had comparable ACQ score reductions (D) at 16 weeks; at 52 weeks, 
omalizumab performed better than mepolizumab 75mg and 750mg (D= -0.25 and -0.20 
respectively, P≥ 86%), and was comparable to mepolizumab 250mg (D= -0.13, P= 75%). 
All active treatments performed better than placebo. In terms of asthma exacerba-
tions, at 16 weeks, omalizumab was comparable to masitinib (OR= 1.30, P= 64%) and 
performed better than placebo, while masitinib was comparable to placebo (OR= 0.60, 
P= 76%). At 26 weeks, omalizumab performed better than placebo. At 16 and 26 weeks, 
active treatments and placebo had comparable discontinuations due to AE rates. 
At 52 weeks, mepolizumab 75mg had lower discontinuations due to AE rates than 
mepolizumab 750mg, and was comparable to other treatments. Omalizumab, mepoli-
zumab 250mg, 750mg and placebo were comparable. cOnclusiOns: This network 
meta-analysis of asthma treatments suggested that omalizumab had greater ACQ 
score reductions at 52 weeks than mepolizumab 75mg and 750mg but was compa-
respectively. For loratadine, a total of 147 TQP reports were submitted, correspond-
ing to 61% male users (mean age 51 years), and 8% and 36% of TQP events were fatal 
and life-threatening, respectively; 65% of reported events contributed to patient 
hospitalization. On average, desloratadine and loratadine users used 3 concomi-
tant medications at the time of TQP occurrence. Reporting of TQP for deslorata-
dine users was more than expected (EBGM= 1.70; 95%CI= 1.13-2.48), but a stronger 
signal was found for loratadine users (EBGM= 3.65; 95%CI= 3.18-4.17). Astemizole 
and terfenadine were associated with significant signals of TQP (EBGM= 20.1; 
95%CI= 17.3-23.3 and EBGM= 15.0; 95%CI= 13.6-16.4, respectively). cOnclusiOns: 
Anti-allergy treatment with desloratadine might be associated with TQP. A non-
arrhythmogenic antihistamine might be an alternative therapy in patients at 
risk of ventricular tachycardias. Cardiac conduction monitoring might be recom-
mended in desloratadine users.
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Objectives: 1 To estimate the prevalence of ADRs including serious/fatal ADRs 
and clinical manifestations. 2 To analyze cost of treatment for serious and fatal 
ADRs. MethOds: the prevalence of AdRs: A cross-sectional descriptive study. 
Data was collected from electronic database in Vajira Hospital during 1 January 
2012-31 December 2013 from inpatient and outpatient departments. Those 
patients had experienced with those ADRs from other hospitals or been diag-
nosed for ADRs by physicians or pharmacists at Vajira Hospital. costs of treat-
ment for serious and fatal AdRs (baht per event) were direct medical costs. 
Costs included drug costs which were obtained from the median price from the 
Drug and Medical Supply Information Center, Ministry of Public Health, cost of 
admissions to hospital and laboratory cost, which were obtained from the unit 
cost of the standard cost for HTA.The Costs were evaluated from the resources 
being used in medical records and verify by physicians. Results: There were 
737 identified ADRs events which consisted of ADRs type A (42events,6%) and 
ADRs Type B (695 events, 94%). Amlodipine was responsible for the most com-
mon ADRs type A (n= 7,17%) for swollen feet while antimicrobial agents, cef-
triaxone was responsible for the most common ADRs type B (n= 69, 10%). 
Majority of manifestation of drug allergies were skin systems (n= 615, 83%).
Serious and Fatal ADRs were showed for 42 events (6%),which antimicrobial 
agents were responsible for the most common causes (ceftriaxone n= 4) followed 
by NSAIDs (Ibuprofen n= 3)and anticonvulsants (Phenytoin n= 4).Direct medi-
cal cost for the treatment of Serious and Fatal ADRs was about 41,000 baht per 
visit. cOnclusiOns: This study provided information to develop the medica-
tion safety policies, which some drugs should be monitored for severe allergic 
reactions.To increase patient safety and reduce costs arising from the treatment 
of those severe allergic reactions,the pharmacists should counsel and educate 
patients to the level that those patients can be able to observe themselves.
PRS3
RiSk oF PneuMonia aSSociateD with the uSe oF icS/laba: a 
RetRoSPective cohoRt StuDy in koRea
Park J1, Shin J2, Bae S3
1Ewha Womans University, AstraZeneca Korea, Seoul, South Korea, 2Korea institute of drug safety 
and risk management, Seoul, South Korea, 3Ewha Womans University, Seoul, South Korea
Objectives: It is well known that the patients treated with fixed combination 
of inhaled corticosteroid/long acting beta-2 agonist(ICS/LABA) shows pneumonia 
as an adverse event. The purpose of this study is to compare the risk of hospi-
talization by pneumonia between two different ICS/LABA substances. MethOds: 
Retrospective cohort study was conducted using 2013 HIRA-NPS(National Patients 
Sample of Health Insurance Review and Assessment Service) database of Korea. The 
cohort consisted of the patients who were prescribed DPI(Dried Powder Inhaler) 
form of fluticasone/salmeterol and budesonide/formoterol at least once as an ini-
tial user from Feb 2013 to Dec 2013. The patients who were enrolled to the cohort 
was observed until the first hospitalization due to pneumonia(J12-18 of ICD-10 
code) occurrence. The incidence rate of pneumonia were estimated and crude and 
adjusted hazard ratio of pneumonia associated with ICS/LABA use with 95% confi-
dence intervals were estimated by Cox proportional hazard model. Results: The 
cohort included 5,939 patients of which 4,531 patients(76.3%) treated with fluti-
casone/salmeterol and 1,408 patients(23.7%) treated with budesonide/formoterol. 
The pneumonia incidence rate was higher with fluticasone/salmeterol which was 
8.50 per 100 person-year while the pneumonia incidence rate of budesonide/for-
moterol was 5.14 per 100 person-year. Compared with budesonide/formoterol, the 
pneumonia risk was higher in patients treated with fluticasone/salmeterol(hazard 
ratio: 1.48, 95% CI: 1.06-2.06). The results were similar in sensitivity analysis which 
regulated definition of initial users. cOnclusiOns: The higher risk of pneumonia 
occurrence was observed for fluticasone/salmeterol which shows the intra-class 
difference of fixed combination of inhaled corticosteroid/long acting beta-2 agonist. 
The difference between the adverse event occurrences should be considered before 
selection of drugs for the patients.
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